Abstract: The present invention relates to a formulation useful to control Listeria monocytogenes that comprises three new lactic acid bacteria, namely Carnobacterium maltaromaticum ATCC® PTA-9380, C. maltaromaticum ATCC® PTA-9381 and Enterococcus mundtii ATCC® PTA-9382 together with the bacteriocin nisin. This formulation is obtained from Inactivated Fermentates (IF) of these strains plus nisin and is designed to be used in the food industry. This formulation is used as an agent with tested antagonistic and bactericidal action against the pathogen Listeria monocytogenes, the microorganism that causes listeriosis, a food-borne disease, in humans. Based on this formulation, 2 surface sanitizing products can be obtained, a liquid and a solid. Both surface sanitizers can be applied to sanitize equipments, devices, working surfaces, gutters and drainages, especially in the food industry.

Abstract: The present invention relates to a formulation useful to control Listeria monocytogenes that comprises three new lactic acid bacteria, namely Carnobacterium maltaromaticum ATCC® PTA-9380, C. maltaromaticum ATCC® PTA-9381 and Enterococcus mundtii ATCC® PTA-9382 together with the bacteriocin nisin. This formulation is obtained from Inactivated Fermentates (IF) of these strains plus nisin and is designed to be used in the food industry. This formulation is used as an agent with tested antagonistic and bactericidal action against the pathogen Listeria monocytogenes, the microorganism that causes listeriosis, a food-borne disease, in humans. Based on this formulation, 2 surface sanitizing products can be obtained, a liquid and a solid. Both surface sanitizers can be applied to sanitize equipments, devices, working surfaces, gutters and drainages, especially in the food industry.

Abstract: The present application is directed to a new Bacillus subtilis strain deposited under the access number ATCC® PTA-8805, to bioproduct formulations comprising viable cells of the new strain, which can be encapsulated or in a concentrated liquid form, and to the use of these bioproducts to biologically control and decrease the incidence of Rhizoctonia solani, a plant pathogen that attacks economically important crops. The bioproducts are applied in encapsulated form directly over tubers or spraying a concentrated liquid form diluted in water over a plantation, and both formulations are applied in covered furrows.

Abstract: A device and method for holding a substrate, e.g., a semiconductor wafer, during a process, e.g., a liquid meniscus process, the substrate having a first side and a second side. The device includes one or more holding components, e.g., fingers, configured to contact a second side of the substrate without significantly contacting the first side of the substrate. At least one of the holding components may be configured to be moved during the process so as to prevent the at least one holding components from effecting the process, e.g., contacting the liquid meniscus. Such an arrangement may be employed when the substrate includes a top side having at least one structure or feature thereon, it being desirable that the holding components avoid contact with the structures or features during the process.

Abstract: A wet processing apparatus and method that takes advantage of a fluid meniscus to process at least a portion of a surface of an object. After one surface of the object has been processed another side or surface of the object can be similarly processed. This processing can be coating, etching, plating, to name a few. An application of the apparatus and method is in the semiconductor processing industry, especially, the processing of wafers and substrates. The method and apparatus also allows the processing of multiple surfaces of an electronic component.

Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D using polymorphisms in the T2D risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D.

Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to CHD or CHD death are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for CHD using polymorphisms in the CHD risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for the prevention and treatment of CHD. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of CHD.

Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to hypertension (HT) are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for HT using polymorphisms in the HT risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of HT. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of HT.

Abstract: Genes, SNP markers and haplotypes of susceptibility or predisposition to CHD such as AMI are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for AMI using polymorphisms in the AMI risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of AMI and CHD. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of CHD and AMI.

Abstract: A role of the human EXT2 gene in metabolic conditions such as T2D is disclosed. Methods and test kits for diagnosis, T2D risk prediction and prediction of clinical course of a metabolic condition using biomarkers related to the EXT2 gene are disclosed. Novel methods for prevention and treatment of metabolic diseases based on EXT2 gene, polypeptides and EXT2 related pathways are also disclosed.

Abstract: A catalyst for polymerizing olefins is the product resulting from mixing in an inert hydrocarbon diluent, a mixture of (A) an inorganic oxide, (B) an organomagnesium material, (C) an organic hydroxyl-containing material, (D) a reducing halide source, and (E) a transition metal compound.

Abstract: A catalyst for polymerizing olefins is the product resulting from mixing in an inert hydrocarbon diluent, a mixture of (A) an inorganic oxide, (B) an organomagnesium material, (C) an organic hydroxyl-containing material, (D) a reducing halide source, and (E) a transistion metal compound.

Abstract: Olefins are polymerized under slurry conditions in the presence of a cocatalyst and a catalyst prepared by a method wherein a mixture (A) containing the product resulting from mixing in an inert hydrocarbon diluent (1) a hydrocarbon soluble magnesium alkyl compound, (2) an aliphatic alcohol and (3) a titanium compound is reacted with (B) a reducing halide source. Components (A) and (B) are mixed at a constant initial temperature. When the concentration of components (A) and (B) in said hydrocarbon solvent is relatively low and when the ratio of the number of moles of aliphatic alcohol:total number of hydrocarbyl groups attached to the metal atom in component (1) is relatively low, the resultant polymer has a relatively small average particle size and a relatively narrow particle size distribution.

Abstract: A method for preparing Ziegler catalysts is disclosed wherein a mixture (A) containing the product resulting from mixing in an inert hydrocarbon diluent (1) a hydrocarbon soluble magnesium alkyl compound in said hydrocarbon solvent, (2) an aliphatic alcohol or carbon dioxide and (3) a titanium compound is reacted with (B) a reducing halide source in said hydrocarbon solvent. Components (A) and (B) are mixed at a constant initial temperature. When the magnesium concentration in component (A) and the metal concentration in component (B) are relatively low, the resultant polymer has a relatively narrow particle size distribution whereas when said concentration is relatively high, the resultant polymer has a relatively broad particle size distribution. When the ratio of the number of moles of aliphatic alcohol:total number of hydrocarbyl groups attached to the metal atom in component (1) is relatively low, the resultant polymer has a relatively small average particle size.

Abstract: Olefins or mixtures thereof are polymerized in the presence of the product resulting from heating in an inert hydrocarbon diluent a mixture of (A) an organomagnesium material, (B) essentially anhydrous carbon dioxide, (C) a reducing halide source and (D) a transition metal compound.

Abstract: A catalyst for polymerizing olefins is the product resulting from mixing in an inert hydrocarbon diluent a mixture of (A) an organomagnesium material, (B) an organic hydroxyl-containing material, (C) a reducing halide source and (D) a transition metal compound.

Abstract: A catalyst for polymerizing olefins is the product resulting from heating in an inert hydrocarbon diluent a mixture of (A) an organomagnesium material, (B) essentially anhydrous carbon dioxide, (C) a reducing halide source and (D) a transition metal compound.

Abstract: A catalyst for polymerizing olefins is the product resulting from a mixture of (A) an organomagnesium material, (B) essentially anhydrous carbon dioxide, (C) a reducing halide source and (D) the reaction product or complex resulting from admixing a transition metal compound and an organozinc compound.

Abstract: Olefins are polymerized in the presence of, as a catalyst therefor, the catalytic reaction product resulting from admixing(A) at least one hydrocarbon soluble organomagnesium material;(B) at least one organic hydroxyl-containing material;(C) at least one reducing halide source; and(D) at least one transition metal (Tm) compound.

Abstract: A catalyst for polymerizing olefins is the reaction product of (A) the reaction product of (1) the reaction product of (a) an alkyl magnesium compound such as dibutylmagnesium, with (b) an oxygen-containing and/or nitrogen-containing compound such as n-propyl alcohol, or isopropylamine, with (2) a halide source such as titanium tetrachloride or silicon tetrachloride; and (B) a transition metal compound such as titanium tetrachloride and (C) a reducing agent such as triisobutylaluminum.Also disclosed is a non-transition metal containing catalyst support for use in preparing olefin polymerization catalysts.The polymers which are produced in the presence of this catalyst and a cocatalyst such as triethylaluminum have a low catalyst support to transition metal ratio and therefore, the catalyst efficiency based on quantity of polymer per quantity of total catalyst is very high resulting in a polymer having good color and very little, if any, corrosion.